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Background: For many decades, access to human biological samples, such as cells, tissues, organs, blood, and
sub-cellular materials such as DNA, for use in biomedical research, has been central in understanding the nature
and transmission of diseases across the globe. However, the limitations of current ethical and regulatory frameworks
in sub-Saharan Africa to govern the collection, export, storage and reuse of these samples have resulted in inconsistencies
in practice and a number of ethical concerns for sample donors, researchers and research ethics committees. This paper
examines stakeholders’ perspectives of and responses to the ethical issues arising from these research practices.
Methods: We employed a qualitative strategy of inquiry for this research including in-depth interviews and focus group
discussions with key research stakeholders in Kenya (Nairobi and Kilifi), and Ghana (Accra and Navrongo).
Results: The stakeholders interviewed emphasised the compelling scientific importance of sample export, storage and
reuse, and acknowledged the existence of some structures governing these research practices, but they also highlighted
the pressing need for a number of practical ethical concerns to be addressed in order to ensure high standards of
practice and to maintain public confidence in international research collaborations. These concerns relate to obtaining
culturally appropriate consent for sample export and reuse, understanding cultural sensitivities around the use of blood
samples, facilitating a degree of local control of samples and sustainable scientific capacity building.
Conclusion: Drawing on these findings and existing literature, we argue that the ethical issues arising in practice need to
be understood in the context of the interactions between host research institutions and local communities and between
collaborating institutions. We propose a set of ‘key points-to-consider’ for research institutions, ethics committees and
funding agencies to address these issues.
Keywords: Human biological samples, Broad consent, Research collaboration, Sample export, AfricaBackground
For many decades, access to human biological samples,
such as cells, tissues, organs, blood, and sub-cellular ma-
terials such as DNA, for use in biomedical research, has
been central in understanding the nature and transmis-
sion of diseases across the globe [1-3]. With the comple-
tion of the Human Genome project in 2003 and the* Correspondence: ptindana@gmail.com
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unless otherwise stated.advent of new high throughput sequencing technologies,
the number of samples that are collected, exported and
stored for reuse have increased. For example, in one pro-
ject, over 100,000 samples have been collected across
several developing countries to explore and identify crit-
ical mechanisms of protective immunity against malaria
[2,4]. This kind of activity is likely to increase with the
recent Human Heredity and Health in Africa Initiative
(H3Africa) which seeks to build genomic capacity in
Africa [5]. Due to limitations of current scientific infra-
structure to process and analyse these samples in many
African research institutions, these samples are oftenl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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boratories in high income countries (HICs) [6,7]. Also,
data derived from the analysis of these samples are often
shared across research institutions.
The practice of exporting and sharing human biological
samples from Africa has led to questions about appropri-
ate mechanisms to safeguard the interests of sample do-
nors; that is research participants and their communities
[8,9]. Specific issues around privacy, benefit-sharing and
consent, and particularly the validity of broad consent and
what consent should be required for sample export, have
been highlighted in the literature [10-14]. For example,
Langat’s study of two Kenyan ethics review committees in
2005 revealed that 25 per cent of protocols reviewed
stated there was a need for sample storage and reuse, but
only half actually informed participants of this at the time
of consent [7]. In a survey of participants in a malaria
clinical trial in Uganda, also in 2005, Wendler et al. found
that most participants were willing to permit sample ex-
port and storage and waive additional consent for future
research, provided the study was approved by an ethics re-
view committee. However, respondents expressed a desire
to be informed about the sorts of studies stored samples
would be used for [11]. In 2010, a survey of patients in
Egypt found that most patients (62%) preferred to have
their samples exported to other Arab countries compared
to Europe and USA [15]. Recently, two qualitative studies
conducted in Nigeria [16] and South Africa [17] reported
general community support for the storage and reuse of
samples but on condition that the appropriate structures
are in place to protect the interests of participants. Over-
all, the literature suggests that research practices involving
human biological samples are increasing; these practices
are generally recognised and accepted as essential to ad-
vance scientific research; but there are concerns which
need to be addressed.
This paper reports on a study which sought to identify
the practical ethical issues arising in the collection, ex-
port, storage and reuse of human biological samples in
the context of international collaborative biomedical re-
search. It is the first study to explore these issues from a
diverse range of research actors in sub-Saharan Africa
(ethics committee members, researchers, fieldworkers and
community members). Specifically, stakeholders’ concerns
about these research practices were sought in addition to
their views about means of addressing them. Our findings
are relevant not only to the countries involved in this
research, but also to wider debates in the sub-region.
Research context and setting
The research was conducted in two research settings in
sub-Saharan Africa: Navrongo in Northern Ghana which
hosts the Navrongo Health Research Centre (NHRC)
and Kilifi in Kenya, which hosts the Kenyan MedicalResearch Institute (KEMRI)/Wellcome Trust programme
(KWTRP). Detailed descriptions of these research insti-
tutions have been reported in previous work by Tindana
et al. [18]; Molyneux et al. [19]. These two research
institutions were purposively selected because they are
both involved in major research activities involving
international collaborations, and have many research
projects involving the collection, storage and in some
cases export of human biological samples. They both
run a longitudinal health and demographic surveillance
system (HDSS) and have had a research relationship
with the host community for over twenty-five years,
both celebrated their 25th anniversary in 2014. These
features provided a platform upon which to address the
research questions for this study. The aim of this study
was not to compare findings from the KWTRP and
NHRC but rather to solicit a broad range of views from
various stakeholders across the two settings about these
questions.
Methods
We adopted a qualitative research approach [20-24], in-
cluding semi-structured interviews and group discus-
sions, to gain an in-depth understanding of the key
issues from the perspectives of those who are informed,
experienced and affected by sample export, storage and re-
use in the context of international research collaborations.
Data collection was carried out in Kenya and Ghana
over a period of six months between October 2010 and
March 2011. A total of 44 interviews (25 in Kilifi and 19
in Navrongo) and six focus group discussions (3 in Kilifi
and 3 in Navrongo) were conducted (Table 1). Inter-
viewees included researchers who design and conduct
research; fieldworkers and research assistants who are
responsible for collecting samples and data, and for en-
gaging with research participants and their communities
(and who often come from local communities); labora-
tory staff responsible for managing and analysing sam-
ples; members of research ethics committees; directors
of research institutions; and community representatives.
Many interviewees were purposively selected from six
projects (three per institution) identified through an
audit of all ongoing collaborative research projects in-
volving the collection, long-term storage and export of
human biological samples.
Themes explored in interviews included rationales for
long-term storage and export of samples, perceptions of
these practices and of the importance of human tissues
to community members, and recommendations for
change in guidelines and practice. Issues raised in earlier
interviews informed later interviews, and were used as
probes to add to our understanding of views. Individual
interviews took 45 minutes to 1.25 hours, and group dis-
cussions approximately two hours. All interviews were
Table 1 Sample of stakeholders interviewed
Research participants Data collection methods Navrongo/Accra Kilifi/Nairobi
Researchers/Research assistants In-depth interviews 12 (10 men and 2 women) 12 (8 men and 4 women)
Cross study key informants (Clinical trials
coordinator, lab manager, community
liaison, training coordinator)
In-depth interviews and group discussion 1(man) 5 (4 men, 1 woman)
Community facilitators and representatives Focus group discussions 1 group 1 group (5 men and 1 woman)
Fieldworkers Focus group discussions 2 groups 2 groups
Ethics committees In-depth interviews 6 (4 men and 2 women) 8 (5 men and 3 women)
Total data collection activities 22 (19 IDIs and 3 FGDs) 28 (25 IDIs and 3 FGDs)
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the community representatives in Navrongo which were
conducted in the local language (Kasem).
Data management and analysis
All the audio-recorded individual interviews and focus
group discussions were transcribed verbatim by trained
transcribers. Two of the interviews were not audio-
recorded and were summarized into a table with notes,
highlighting the key points raised by the interviewees.
Verified transcripts were then imported into Nvivo 8 to
facilitate the analysis process.
Data analysis was on-going throughout the study,
using a thematic approach [25,26]. Codes were guided
by the objectives of the study and from a close reading
of the interview transcripts. Some codes were descriptive
such as types of samples, destination of exported samples,
types of study/project, ethics review, while others were
conceptual such as consent, fairness, trust, luck, agree-
ments, integrity. Over time, codes were further collated
into categories such as nature of research collaborations,
challenges with seeking consent, fairness/justice, govern-
ance, capacity building and trust relationships.
Ethical considerations
This research was approved by the Oxford Tropical
Research Ethics Committee (OXTREC 11.10), the
Navrongo Health Research Centre Institutional Review
Board (NHRCIRB092) and the KEMRI/National Ethical
Review Committee (SCC 1818). Written consent was ob-
tained from all the stakeholders interviewed. All partici-
pants were assured of confidentiality.
Results
There was a general consensus among all stakeholders
in this study that there are compelling scientific reasons
for the collection, export, storage and reuse of human
biological samples for research purposes. There was also
general community support for biomedical research.
However, a number of practical ethical challenges were
identified as important and requiring careful consider-
ation in developing models of good research practice.These include cultural sensitivities around the use of
blood samples, concerns with broad consent (defined as
consent that allows the use of biological samples and as-
sociated data in specific immediate research and future
research with ethics approval and for opportunities for
withdrawal of consent), given the inevitable uncertainty
of future uses, perceptions of unfairness in who gains
from sample export and storage, and fears of losing con-
trol of samples after export. In the following section, we
discuss each of these themes in turn, followed by an
overall discussion on the importance of local capacity
building and effective research governance.
Local sensitivities around the use of blood samples
Stakeholders reported that although other human sam-
ples such as stool, urine and throat swabs are collected
for research purposes, there are particular community
apprehensions about the use of blood samples in re-
search. This makes seeking consent for blood sampling a
general and major background concern in these research
settings; a concern inevitably interwoven with sample
export and storage. Apprehensions with blood sampling
include possible pain for children, and the potential of
the volume of blood taken to cause harm, particularly to
sick children. The latter concern is further complicated
by the local words for ‘anaemia’, a common problem, dir-
ectly translating to ‘not enough blood’.
“I think what the mothers seem to imply is that if you
take blood out of my child he/she gets weak. And that
makes sense. If you’re cut and you bleed a significant
amount you get weak. So for them they can’t correlate
how much is too much blood to make my child feel
weak. And also it’s distressing to them that their child
is being bled” (Kilifi, RES04, Female).
Interviewees suggested that these worries can be a
much greater concern than sample export, and storage:
“I think in some of the consent forms it is included
that the blood may be exported outside for further
tests, and usually during consent no issues are raised -
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cially for children, that mothers become apprehensive”
(Navrongo: RES08, Female).
Stakeholders also reported some rumours and ap-
prehensions in the community about researchers ‘sell-
ing blood’ in both Kilifi and Navrongo and about
‘devil-worshiping’ specifically in Kilifi. Fieldworkers
from and living within local communities attributed
these concerns in part to confusion caused by explana-
tions of sample export:
“There is a whole mix up between misconception and
then maybe misinterpretation because when they hear
the word “transport”, that notion that all the blood
samples are transported separately is not in their
mind. They think that all the blood is put together
and put in the ship so there is that feeling that if this
blood is transported and maybe they think that it is
put into buckets, so there is that feeling that they are
doing something dubious with this blood because
transporting to them and even to me might mean
many things packed together to outside countries”
(Kilifi: Group Discussions with Fieldworkers-FW 01).
In both Kilifi and in Navrongo, fieldworkers and com-
munity representatives reported that the practice of
‘buying blood’ for blood transfusions in clinical settings
has also fuelled rumours about selling of blood. As a
community representative explains:
“When people go to the hospital and they say you are
short of blood, they say look for people to give you
blood if not buy at the blood bank, so the first idea
that came to them was that probably that was [the
NHRC’s] way of taking blood from the people to go
and sell to patients at the hospital” (Navrongo:
Community Representative −03, Male).
That these perceptions are strongly held is illustrated
by several researchers in Kilifi and Navrongo reporting
that some mothers of study participants had approached
them to ask if blood that had been collected from their
children during the course of a research project could be
given back to them for transfusion.
In both settings however, it was also recognised that
underlying concerns with blood taking include people’s
special attachment to blood and (mis)trust:
“…there’s that connection with the past where people
generally were used for other people’s financial gain.
It’s all connected to the way people have been treated
in the past and that maybe difficult, to disconnect”
(Kilifi: RES03, Male).“I think traditionally blood is life and traditionally
there are attachments and stories linked to blood.
Especially when it comes to research. It goes back to
our great grandfathers who attributed blood to the
initial white men who used to come and steal blood
and just run away so when you talk about blood it
triggers many memories and that’s why you have to be
very careful” (Kilifi: Group Discussions with
Community Facilitators).
The above concerns contribute to consent for blood
sampling often being far from straightforward, and
some researchers feeling that they have a responsibility
to handle samples that have been entrusted to them
appropriately:
“It's not been easy getting consent to take blood
samples from participants and so after explaining
deeply about what we are doing, one always has to be
careful to protect the blood and to make sure that it's
used for what it has been collected for. Participants
always have concerns about what the blood will be
used for” (Navrongo: RES08, Female).
To address concerns about blood sampling, export
and future uses, stakeholders recommended strengthen-
ing understanding of scientific research and of projects
that involve human biological samples. Most proposed
engaging the general community as well as participants
through mechanisms such as incorporating videos into
consent processes; videos of what happens to samples
and of analytical processes being performed. Most inter-
viewees felt that videos would help potential research
participants understand what it means to collect a quan-
tity of blood from a participant and visualize how these
samples are actually analysed.
“…I think we need some kind of audio visual kind of
demonstration of the process of taking the sample from
the research participant to processing that sample and
establishing what really it is we have found in that
sample and then how the rest of the sample that we
have taken is handled for people to physically and
mentally imagine what the samples we take from
them go through” (Navrongo: REC 01, Male).
Open days for local residents to visit the institutions’
laboratories were also frequently suggested:
“We need to go beyond just talking to them but maybe
even invite people from some of the communities to
come and visit our laboratories. … they should come
and see what really happens… come and see how their
blood ends up so that it can help to dispel some of the
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things remain entrenched and it has some
implications for the work that we do” (Navrongo:
RES03, Male).
There are on-going community engagement initiatives
in both settings, including the above recommended ac-
tivities in Kilifi. Of interest in Kilifi is that some activities
aimed at responding to community suggestions and re-
ducing concerns, has introduced new worries. For ex-
ample removal from vehicles of the research institutions’
logo (which includes a snake and has reportedly fuelled
devil worship rumours), prompted new concerns about
what the institution has to hide:
“…even after the logo had been removed, that created
a whole lot of issues surrounding the snake logo”
(Kilifi: Group discussions with fieldworkers -FW01).
These responses suggest that there are limits to how
much communication can address some of the more
fundamental underlying issues and concerns that were
raised above including historical and on-going (mis)
trust. Several researchers also hinted that there is a limit
to how much sampling for research can be promoted in
these settings, and to a responsibility among researchers
to minimise volumes of blood requested:
“I think there’s got to be a balance here, on the one
hand we know that to enjoy health and have good
medical care…..research has to go ahead to develop
tools and this knowledge that is required and for
research to go ahead it needs samples. On the other
hand I think as researchers we must not therefore use
this as a blackmailing tool to the community and
demand blood as if we’re vampires (laughs) I think
we’ve got to be very sensitive and very judicious as to
how much blood we get” (Kilifi: CSKI01, Male).
Views on broad consent and future uses of samples
Overall, the difficulty of explaining future uses of samples
when these are uncertain at the time of sample collection
was widely recognised:
“I would say the consenting process is difficult because
to be able to tell the person who is providing the
sample all the possible research questions that it’s
going to answer at the time of collection is not possible
and also as technology is advancing, even if one had
intended to do an analysis using a particular kind of
machine or a particular kind of process one maybe
able to get more information than originally intended
just by using a more sophisticated technology”
(Nairobi: REC00, Female).Ongoing debates in the literature about the validity of
broad consent for future uses of samples were reflected
in discussions in this study. Some interviewees argued
that since the requirements of full disclosure cannot be
assured in broad consent, this cannot be considered as
valid consent:
“This is certainly not valid. What is the consent all
about? That you have explained the purpose of the
research to the person, the risks and benefits of the
research to the individual and s/he has granted
consent. So you don’t know the risks involved in using
those future samples for any other type of research? How
can that be consenting to something that I don’t know.
Certainly, people cannot behave that way. We have seen
it in a couple of consent forms and this IRB has really
been critical about that” (Navrongo: REC03, Male).
Some researchers noted that whatever is actually said
in the consent form, there is a potential for ‘abuse’:
“…. you cannot rule that out because some scientists
may go beyond the boundaries and want to do other
things that initially were not disclosed to the study
participant. Even though in the consent form, they say
these aspects would not be included in whatever analysis
they are going to do” (Navrongo: RES013, Male).
Most stakeholders, especially RECs, fieldworkers
and community representatives, recommended a re-
examination of current approaches to consent for
reuse of samples. The majority view was that it is im-
portant to move away from granting blanket consent
(defined as consent that allows the use of biological
samples and associated data for future research of any
kind at anytime without restrictions). According to
RECs in both Nairobi and Navrongo, there are limits
to the acceptability of broad consent. They expect re-
searchers to state in clear terms what stored samples
will be used for in future and not to be vague or too
general, to avoid possible misuse. One of the implica-
tions of this is that it would also require limiting the
future use of these samples, for example, to the dis-
ease studied during the initial consent:
“..what we have tended to do is to say future –
“related”- research, so if you are collecting the samples
for malaria research, that future research should be
malaria related, it cannot be HIV or something that
has nothing to do with the initial purpose for which
the samples were collected” (Navrongo: REC01, Male).
There is a potential tension between this position from
the RECs and that of researchers who highlighted the
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context of which these RECs’ expectations and require-
ments for specifics appear problematic. There was there-
fore a general appeal from researchers for caution in the
implementation of guidelines and policies governing
these research practices:
“If you’re doing research you can’t completely know
what the next step is because if you did then you
wouldn’t be doing research, you’d just be exploring the
known. But if you’re exploring the unknown you can’t
anticipate, you can’t anticipate everything you’re going
to do” (Kilifi: RES03, Male).
Most researchers and RECs recommended that the de-
cision to return to participants and their community to
re-consent to future uses of samples should be deferred
to the local REC. Given that re-consenting individuals
may often be difficult, community engagement – specific-
ally consultation with community representatives – was
generally seen as one option to decide on whether individ-
ual re-consent is necessary in particular situations. This
process could also help researchers to identify and address
particular local sensitivities with proposed analyses.
“Re-consenting participants is very difficult but we
must find a way of involving the community in the
decision making process” (Nairobi: REC09, Male).
“…if you use those particular samples for any future
research without the knowledge of the community or
the donors, if any publication comes out that is
adverse, that has consequences for … those particular
communities. They could give consent for future use of
samples, the community members might not know the
implications of that but then when you publish the
document and then information is trickling down that
oh, you say that in this particular community, women
are more likely to deliver kids who end up being
prostitutes in future, that community would be
stigmatized and then they get to realize that no, you
didn’t treat them fairly” (Navrongo: REC03, Male).Researchers’ concerns over sample export: Who gains
from research samples?
According to most of the KWTRP and NHRC researchers
interviewed, although scientific collaborations are often
based on a mutual agreement — the details of which are
sometimes spelt out in a material transfer agreement
(MTA) — there are often concerns about who will ultim-
ately control the management of transferred samples.
Most NHRC researchers raised concerns that local re-
searchers and host institutions would be unable to controlhow the samples are eventually used once the samples and
data leave the local institution:
“Once the samples get out there, the local
collaborators do not really have any control as to who
uses it and if it is used and there has to be
publications, who should be part of that publication –
there should be fairness in the attribution of the
contributors to generate knowledge out of that”
(Navrongo: RES13, Male).
Although most researchers indicated that they were
aware of what the samples are expected to be used for
and how they are to be destroyed and/or used up, some
reported that they are unable to account for transferred
samples:
“But it is difficult for me to say I know exactly where
these samples are. I know there’s one institution,
three institutions, maybe four institutions in the
US [involved] but I can’t tell you exactly what is
happening. But I know some of the collaborations –
but I can’t tell you exactly the outcome of the on-going
assays” (Kilifi: RES05, Male).
There were views that the tendency for there to be a
lack of feedback about the fate of exported samples
leads to suspicions that samples may be used for other
purposes or analysis without the knowledge of the con-
tributing researcher. Furthermore, in the absence of
feedback, local researchers might assume that they have
samples stored in external laboratories when in reality
they have been used up and destroyed after the analysis.
Another concern raised was the lack of recognition for
local researchers’ contributions in scientific research col-
laborations. Many researchers alluded to authorship in
scientific publications as a concern and expressed a
worry that someone else might end up taking the credit
for research results. Some NHRC researchers cited in-
stances where some collaborators had used samples and
data without acknowledging the local researchers and
the community:
“Internally I have seen how the samples are handled
in other collaborating labs within country where
people just pick aliquots of the sample, run their
studies, you meet them in international circles, they
are making presentations, you see the map of
Navrongo and you know that the presenter does not
even know Navrongo but you know that this work has
come from samples that were taken from a study you
were part of, we are not acknowledged, the community,
the participants are not acknowledged” (Navrongo:
RES05, Male).
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some of us who had worked on that project tirelessly
were never included in the publications” (Navrongo:
RES15, Male).
Most researchers suggested that issues such as local
control of samples and proper recognition remain per-
tinent as long as the samples are leaving the immediate
environment of the donors and collectors of the sam-
ples, even to other parts of the country or within
south-south initiatives. This highlights the importance
of perceptions of what might perhaps be thought of as
‘moral distance’:
“.. it doesn’t really mean that the concerns or the
issues will be resolved if samples do not go beyond the
boundaries of Africa. As long as the sample leaves
your immediate lab, I mean the issue of control and
access that we are talking about is the same. I don’t
think it is easier to go to South Africa than it is to go
to New York. I think in many cases it is even easier to
go to New York” (Navrongo: REC01, Male).
“I am an African, a very proud one but I think .. we
must not make the issues African or non-African, we
should be a bit more objective than that. If I must
handle the samples and test them, I must do so not be-
cause I am an African but because I would deliver the
expected good results” (Kilifi: CSK01, Male).
Research ethics committees’ concerns about the fate of
exported samples
Local researchers are not the only stakeholders with
concerns about the fate of samples once they have been
exported. REC members in Nairobi and Navrongo
expressed concerns about their inability to control what
happens after granting approval for sample export:
“…once the samples have left our jurisdiction we really
have no control over it. And this is something that
really we need to look into, how best can we control
the samples that have left here, how best can we
ensure that they’re used for the purpose that they were
taken and they’re not used for another study” (Nairobi:
REC04, Female).
Currently, there are no mechanisms in place to deter-
mine the fate of exported samples. According the stake-
holders interviewed, material transfer agreements are
not common and until recently were not required by
many local RECs. A recent requirement in Kenya is for a
local scientist to accompany the samples to the external
laboratories as a way of building local personnel capacity
and to provide some assurances that the samples are notbeing used for unapproved research. Although it was not
clear if this happens in practice, a REC member in
Nairobi explained that this mechanism will also allow
for research sustainability at the local level:
“We feel that for sustainability of research … there
should be somebody who would be able to continue
spearheading and training others to continue with
that intervention and to improve on any intervention
that comes as a result of research” (Nairobi: REC00,
Female).
Some researchers questioned the feasibility of this re-
quirement and suggested that projects should be consid-
ered on a case-by-case basis. REC members expressed
an expectation that although they are unable to monitor
the fate of samples overseas, the host institutions could
take responsibility for the action of their local researchers
and keep the REC updated on the outcome of overseas
analysis. This places an additional responsibility on the
host institution and local researchers to ensure that their
external collaborators are also accountable:
“But when it leaves our jurisdiction, that is where we
have no control over it, extra additional ethical issues
arise. we always demand to know where it is going to
be stored and who is going to be responsible for it out
there. This is all in an effort to protect the participant
to ensure that even though the sample has left our
custody or our control, we transfer this responsibility
to another person and another institution. It’s always
our belief that they will comply and use it for that
purpose only but again as I said it is something that
is based on trust” (Nairobi: REC11, Male).
Group discussions with the KWTRP community facilita-
tors also highlighted the limitations of RECs to monitor
the fate of exported samples:
“If you talk about exporting samples, so long as it’s
being used for the right thing, for the right reason,
that is okay but we don’t know, currently we have no
structures – even when we talk about ERC, the ERC
is there as an academic structure but there are no
structures in place to say we are going to monitor to
see what happens” (Kilifi: group discussions with
community facilitators).
These responses highlight the local concerns and
uncertainties surrounding sample export and the need
to identify ways of ensuring that samples that leave
the immediate environment of its donors and contrib-
utors are used only for agreed and approved research
purposes.
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research governance
It is worth noting that none of the stakeholders advocated
a complete ban on sample collection, export, storage and
their reuse and all acknowledged the importance of med-
ical research with an international collaborative dimension.
There were also reports of research collaborations that
have worked well based on mutual trust, transparency, re-
spect and the scientific leadrship at the institution. Never-
theless, against this background, almost every interviewee
expressed the view that it would be desirable to have more
effective protective measures and assurances to allay the
concerns arising in practice. Potential solutions proposed
by interviewees included local capacity strengthening and
sustainable research partnerships and relationships.
Regarding local capacity strengthening, most interviewees
suggested that international research collaborations should
provide more opportunities for strengthening the scientific
capacity of host African institutions. These should involve
not just the technology and infrastructure needed for the
analysis but also training and retaining of local personnel
with specialized skills to contribute to the conduct, analysis
and publication of research locally. Researchers expressed
the view that it is more efficient to conduct good research
if the required capacity is available locally:
“….it’s much easier for us to do good science if we have
the capacity to do it here. I think we move forward
faster if we have up to date technologies here and staff
that are suitably qualified to do it. … we’re also keen
to make sure that we’re developing local scientists so
it’s not the science of the project that’s governing it, it’s
the need for developing a group of scientists for the
future of this region” (Kilifi: RES07, Male).
Specifically highlighted was the need to ensure cap-
acity for analysis locally to minimize sample export:
“I think that there is a need to rather build capacity
here. you know there's too much talk about what
happens to samples. I believe all those things will
cease to be a problem if the samples were to be
analysed here” (Navrongo, RES03, Male).
Nevertheless, some researchers cautioned that while
local capacity strengthening is essential, the nature of
some research projects will require the sharing of sam-
ples, including overseas sample storage, and thus it is
important for all research actors to keep an open mind
and not assume that sample export will always lead to
exploitation of contributing scientists in Africa.
“..what is important is the whole research process and
researchers’ intentions not to do anything that willbe detrimental to individuals and communities”
(Kilifi: RES01, Male).
Most stakeholders also highlighted the centrality of
effective research governance mechanisms, including the
important gate-keeping role of RECs and the need to
have clear institutional and national policies and guide-
lines governing these research practices. Most inter-
viewees suggested that, RECs are the most appropriate
system for governing research involving human partici-
pants including serving as gate keepers of research samples.
Both researchers and REC members suggested that RECs
could advise researchers on when communities should be
consulted, and if participants should be individually re-
contacted for their consent for future research projects:
“I think that role of export should clearly be defined
and supervised by the IRB to make sure that the
community’s interest is also preserved” (Navrongo,
RES07, Male).
“Now the IRBs are there actually to protect the subjects,
so I think in certain circumstances they should be able
to speak on behalf of the subjects especially if the subject
has in the past given them that blanket storage. the IRBs
we presume would have been keeping abreast with how
things have gone so they should have the power to say
that well we think you should be able to go ahead, we
are standing in trust for them but at the same time too
they should also be able to use their judgment to say
that for this particular one we think you still need to go
back to the subjects to go and see them, so they should
serve as a sieve” (Navrongo, RES17, Male).
A further point suggested above is for RECs to serve
as trustees of research samples. Despite the current chal-
lenges with the REC system, many interviewees were of
the view that RECs should be given the needed logistic
and training support to enable them serve as effective
gate-keepers of research samples. It is worth noting that
fieldworkers and community representatives in both
Kilifi and Navrongo did not specifically mention RECs as a
solution spontaneously but only supported the idea of such
a system only when they were prompted in the interviews.
Discussion
In our analysis, we observed that the ethical issues aris-
ing from the collection, export and reuse of samples are
inter-related. Thus, there is the need to discuss and
understand these issues from the perspectives of all re-
search actors and in the context of the research inter-
actions between host research institutions and local
communities (what we refer to as micro-level issues)
and interactions between collaborating institutions
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differences between the different sexes and age groups
in our analysis of the data. The major differences in
opinion had more to do with the number of years re-
spondents had been exposed to research and their
roles in the research institution.
Our data suggest that biomedical research is evolving
rapidly and its success in the future will increasingly
depend on access to human biological samples and col-
laborative partnerships. This is consistent with current
literature on biobank research highlighting the import-
ant societal value of biobanks in advancing biomedical
research [8,27-30]. It is also suggested that biomedical
research is a complex and expensive enterprise requiring
the pulling together of expertise and resources to achieve
important research goals which include alleviating suffer-
ing, advancing knowledge, preserving life and promoting
human well-being. Thus, research collaborations will
continue to be a key way of moving both the science and
ethics of research forward [5,31,32]. Our research supports
the findings of previous empirical studies in Africa in
identifying a high level of general support for biomedical
research activities in Africa [17,33,34]. However, there is a
pressing need for a number of practical ethical concerns
to be addressed in order to ensure high standards of
practice and maintain public confidence in international
research collaborations, particularly those involving the
collection, export and reuse of human biological samples.
At the micro-level are local concerns about the use of
blood samples in research which have resulted in ru-
mours about too much blood being taken, blood-selling
and devil worshipping, as reported in the past in these
research settings [19,35]. Interviewees in this study at-
tributed these concerns in part to the perceived lack of
understanding, unfamiliarity, uncertainties and complex-
ities associated with novel research projects such as gen-
etic and genomic research. Thus one proposed solution
is to identify innovative and effective ways of communi-
cating the rationale for these scientific research practices
to all research actors including fieldworkers, community
representatives and research ethics committees to allay
these local fears. However, it was also evident that there
are deep cultural sensitivities around the use of blood in
general which need to be taken seriously. Although we
did not seek to compare our findings with non-African
perspectives, our data suggests that cultural sensitivities
around blood samples are more pronounced in these
African settings because of their historical background
and cultural attachment to blood. The concerns raised
in this study support other claims in the literature
linking historical accounts with people’s perception of
medical research in general and the local community’s
view of some research institutions in Africa as ‘blood-
stealing’ organizations [35-37]. As these scholars havealso suggested, these cultural sensitivities reveal how local
communities are responding to their relationships of
dependence and inequality with host research institutions
[37]. This raises issues of justice and benefit-sharing as
ethical concerns, which require serious attention in deter-
mining whether research is ethical or not.
To address concerns about the validity of broad consent,
many stakeholders interviewed have proposed the need to
identify innovative ways of meaningfully engaging sample
donors and their communities, particularly on decisions
around the future uses of samples. Clearly, with the grow-
ing recognition that research with human biological sam-
ples have implications for the wider community and
population, most of these suggestions are calls for extend-
ing the ethical principle of respect for persons to commu-
nities as well. It is worth noting that both KWTRP and
NHRC have established mechanisms for communicating
with local residents about the institutions’ research
activities. The processes involved in these CE strategies
have been reported elsewhere [18,38,39], and include
regular interactions with networks of voluntary commu-
nity representatives to consult with, public meetings with
the general public and community leaders in local villages,
community member visits to the research institution, and
fieldworker support and training [39,40]. Interviewees in
both sites were confident that these engagement activities
are effective ways of improving research literacy and
strengthening the trust relationship between the host in-
stitutions and the community. In Kilifi for example there
are on-going in-depth consultative activities with a diverse
range of community members on appropriate forms of
benefit-sharing for research, including for studies involv-
ing blood sampling [41,42]. There are also examples of de-
liberative processes that have proved useful in soliciting
public views that could be explored in specific contexts
[43,44]. However, what remains unclear is the extent to
which sample donors and communities should be involved
in decisions around future uses of samples. Further empir-
ical studies on what methods of community engagement
will be most effective in this process would be desirable.
At the macro-level, this research highlights concerns
among African researchers and research ethics commit-
tees on the fate of exported samples and who stands to
gain in research collaborations. These responses also
suggest that the issue about local control of research
samples and proper recognition does not disappear
because the collaboration is just between African institu-
tions. What is important is the nature of the relation-
ship, especially one of trust, that is developed between
the various research actors in the collaboration. While
some stakeholders have suggested the need for strength-
ening the capacity of host research institutions to enable
much of the research process to be conducted locally
and to enhance local control of samples, it was also
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eliminate sample export. These include requirements for
uniformity of analysis, quality control and the growing
demands for sample and data sharing. Researchers’ con-
cerns are also based on principles of justice and calls for
some assurance that, irrespective of where research takes
place, the interests of the less dominant partners in the
collaboration (host African institutions, participants and
communities) will be adequately protected, against the
background of inevitable sample export. This can also be
achieved through clear, transparent and fair research
agreements [45,46] as well as ensuring feedback and ac-
countability on the fate of exported samples. These pro-
cesses are important to bolster host communities’
confidence in the research enterprise and to protect par-
ticipants and communities from the effects of misplaced
trust.
Conclusion
Based on our interpretation of this data, we conclude
that many of the ethical issues arising in practice cannot
be taken in isolation but need to be understood within
the context of the interactions between host research
institutions and host communities (micro-level) and
those between collaborating institutions (macro-level),
which in turn are embedded within broader historical and
current global contexts of inequity. Secondly, current eth-
ical standards such as requirements for consent and re-
search ethics committees have limitations in responding
to the complex, unpredictable and uncertain ethical issues
arising from sample storage, export and future research
uses. Last but not least, appropriate forms of trust-building
and assurances through better consent and community
engagement strategies and governance mechanisms are im-
portant in moving both the science and ethics of inter-
national biomedical research forward and in ensuring the
development and implementation of high ethical standards
in international collaborative research practice.
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